Mattel Inc vs Vaxcyte Inc. Common Stock — how do they compare? Mattel Inc trades at $16.65 (market cap $4.80B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 2.2× Mattel Inc's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mattel Inc for 97 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| MAT | PCVX | |
|---|---|---|
Market Cap | $4.80B | $10.51B |
Volume | 4,615,998 | 2,644,694 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.16 | $73.82 |
52-Week Low | $12.66 | $40.32 |
Typical Hold Time | 97 Days | 0 Days |
Enterprise Value | $7.02B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $16.65, down 0.66% with mixed technical signals showing bullish moving averages but overbought RSI levels. The company maintains stable revenue around $5.3-5.5B with 7.78% net margins and attractive valuation ratios (P/E 12.53, P/S 0.93). Recent CEO transition and takeover interest from Authentic Brands Group create significant near-term catalysts, though earnings have shown volatility with two recent quarterly misses.
The stock presents a compelling risk-reward with strong brand portfolio and takeover speculation offsetting execution risks during leadership transition. Analyst consensus leans bullish (54% buy ratings) with $16.25 price target, though investors should monitor new CEO's strategic direction and Barbie sales stabilization. Cash flow volatility and debt levels ($2.33B) remain key watchpoints.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →